August 2009
Pharmaceutical Representative;Aug2009, Vol. 39 Issue 8, p10
The article offers updates related to research and development activities of pharmaceutical companies. Neovacs, a biotechnology company, is planning to implement a Phase II study of its TNF-alpha Kinoid for patients with rheumatoid arthritis. Merck & Co. has started the Phase III clinical study of their Stimuvax cancer vaccine for patients with inoperable breast cancer. Pfizer has stopped their SUN1122 trial which evaluate the Sutent plus Folfiri versus Folfiri alone.


Related Articles

  • Pharmaceutical Companies.  // njbiz;7/4/2005, Vol. 18 Issue 27, p136 

    Presents the top pharmaceutical companies based on the number of employees in New Jersey from 2005 to 2006. Johnson & Johnson; Merck; Bristol-Myers Squibb; Pfizer;

  • Researchers cut loose as Pfizer and Merck shutter European sites. Subbaraman, Nidhi // Nature Biotechnology;Apr2011, Vol. 29 Issue 4, p299 

    The article discusses the layoffs and downsizing being experienced by the drug industry in Europe. It cites an announcement by Pfizer of its planned closure of its research center in Sandwich, Kent by the end of 2012 which can terminate 2,400 research positions in Great Britain and add to the...

  • Sustainable Investment. Drakulich, Angie // BioPharm International;Feb2012, Vol. 25 Issue 2, p7 

    Information about the J.P. Morgan Global Healthcare Conference 2012 held in January in San Francisco, California is presented. The event was attended by 9,000 people from the pharmaceutical industry which discussed key opportunities for investment and the need to reboost research and development...

  • 4Q R&D for Pharma & Biopharma.  // Contract Pharma;Mar2014, Vol. 16 Issue 2, p43 

    Several charts are presented which provide information on the research and development spent and sales of several pharmacies as of March 2014 including Pfizer, Novartis, and Merck & Co. Inc.

  • Biopharma's Engine Room. Looney, William // Pharmaceutical Executive;Dec2014, Vol. 34 Issue 12, p38 

    The article presents a roundtable discussion between executives from the biopharmaceutical industry. Topics discussed include increasing drug development times and research and development (R&D) costs, operational management, and opportunities for new product development. The executives involved...

  • TOP 50.  // Pharmaceutical Executive;Sep2003 Supplement, Vol. 23, p30 

    Presents the top 50 pharmaceutical companies in the U.S. Pfizer; GlaxoSmith Kline; Merck.

  • Patient outreach: Merck, Pfizer develop cancer resource, disease management programs.  // Medical Marketing & Media;Aug2000, Vol. 35 Issue 8, p19 

    Reports on initiatives launched by pharmaceutical companies Merck and Pfizer designed to play a greater role in patient therapy than just providing and promoting drugs. Merck's disease management initiative for patients taking Fosamax for the treatment of Padget's disease; Pfizer's...

  • prescription drugs. Bittar, Christine // MediaWeek;04/23/2001, Vol. 11 Issue 17, pSR22 

    Deals with the advertising efforts of pharmaceutical companies in the United States for its prescription drugs. Popularity of direct-to-consumer drug advertising and the expectation in its increase for the year 2001; Results of the advertisements released by Merck company for its Vioxx...

  • Pharma: Other News To Note.  // BioWorld Today;5/23/2013, Vol. 24 Issue 99, p10 

    This section offers news briefs on pharmaceutical financing including the signing of an accelerated share repurchase (ASR) agreement by Merck & Co. Inc. with finance firm Goldman Sachs & Co. and the splitting off via an exchange offer of the remaining interest of Pfizer Inc. in Zoetis Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics